Monomethyl auristatin E (Synonyms: MMAE; SGD-1010; Vedotin)

目录号: HY-15162 纯度: 99.97%: FAQs
Data Sheet SDS COA 产品使用指南

摩尔计算器

Monomethyl auristatin E (MMAE; SGD-1010) 是海兔毒素 10 的合成衍生物，通过抑制微管蛋白聚合而起到有效的有丝分裂抑制作用。 MMAE 广泛用作细胞毒性成分制作抗体偶联活性分子 (ADCs) 用于癌症的研究。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Monomethyl auristatin E Chemical Structure

CAS No. : 474645-27-7

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
5 mg	￥250	In-stock
10 mg	￥400	In-stock
50 mg	￥690	In-stock
100 mg	￥950	In-stock
250 mg	￥1450	In-stock
500 mg	￥2500	In-stock
1 g		询价
5 g		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of Monomethyl auristatin E:

MMAE-d₈ In-stock
Monomethyl auristatin E (GMP) In-stock
Monomethyl auristatin E (Standard) In-stock

MCE 顾客使用本产品发表的 40 篇科研文献

Proliferation Assay

: Monomethyl auristatin E purchased from MCE. Usage Cited in: Sci Rep. 2016 Apr 21;6:24954. [Abstract]; LC-MS/MS analysis quantified the MMAE concentration in the tumors 3, 24, and 72 h after the administration of MMAE alone. The contents of MMAE in the tumor tissues 3, 24, and 72 h after administration are 1155 ± 609, 736 ± 319, and 413 ± 88 fmol/g (mean ± SD, N = 5 for each group), respectively.

Monomethyl auristatin E 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 ADC Cytotoxin 亚型特异性产品:

查看所有亚型

Auristatin Calicheamicins Camptothecins Daunorubicins/Doxorubicins Duocarmycins Maytansinoids Pyrrolobenzodiazepines Traditional Cytotoxic Agents

生物活性
实验参考方法
纯度 & 产品资料
参考文献

生物活性

Monomethyl auristatin E (MMAE; SGD-1010) is a synthetic derivative of dolastatin 10 and functions as a potent mitotic inhibitor by inhibiting tubulin polymerization. MMAE is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) to treat several different cancer types.

IC₅₀ & Target

Auristatin

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
A549	EC₅₀	0.0005 μM Compound: Monomethyl auristatin E	Antiproliferative activity against human A549 cells after 72 hrs by MTS assay Antiproliferative activity against human A549 cells after 72 hrs by MTS assay	[PMID: 28972755]
A549	IC₅₀	0.59 nM Compound: MMAE	Antiproliferative activity against human A549 cells after 4 days by XTT assay Antiproliferative activity against human A549 cells after 4 days by XTT assay	[PMID: 23845743]
A549	IC₅₀	1.3 nM Compound: 2; MMAE	Cytotoxicity against human A549 cells after 2 days by cell titer 96 aqueous one solution based assay Cytotoxicity against human A549 cells after 2 days by cell titer 96 aqueous one solution based assay	[PMID: 29454703]
BT-474	GI₅₀	0.22 nM Compound: 4, MMAE	Cytotoxicity against human BT474 cells assessed as cell viability incubated fore 4 days by MTS assay Cytotoxicity against human BT474 cells assessed as cell viability incubated fore 4 days by MTS assay	[PMID: 25431858]
BXPC-3	GI₅₀	> 1.39 nM Compound: 2b	Growth inhibition of human BxPC3 cells incubated for 48 hrs by MTT assay Growth inhibition of human BxPC3 cells incubated for 48 hrs by MTT assay	[PMID: 28211277]
BXPC-3	GI₅₀	> 1.39 nM Compound: Desmethylauristatin E	Growth inhibition of human BxPC3 cells after 48 hrs by SRB assay Growth inhibition of human BxPC3 cells after 48 hrs by SRB assay	[PMID: 28926240]
BXPC-3	GI₅₀	> 1.39 nM Compound: Desmethylauristatin E	Growth inhibition of human BxPC3 cells after 48 hrs by SRB assay Growth inhibition of human BxPC3 cells after 48 hrs by SRB assay	[PMID: 28895394]
CWR22R	CC₅₀	1.44 nM Compound: MMAE	Cytotoxicity against human 22Rv1 cells expressing PMSA measured using MTT assay Cytotoxicity against human 22Rv1 cells expressing PMSA measured using MTT assay	[PMID: 34797052]
DU-145	GI₅₀	0.418 nM Compound: 2b	Growth inhibition of human DU145 cells incubated for 48 hrs by MTT assay Growth inhibition of human DU145 cells incubated for 48 hrs by MTT assay	[PMID: 28211277]
DU-145	GI₅₀	0.418 nM Compound: Desmethylauristatin E	Growth inhibition of human DU145 cells after 48 hrs by SRB assay Growth inhibition of human DU145 cells after 48 hrs by SRB assay	[PMID: 28926240]
DU-145	GI₅₀	0.418 nM Compound: Desmethylauristatin E	Growth inhibition of human DU145 cells after 48 hrs by SRB assay Growth inhibition of human DU145 cells after 48 hrs by SRB assay	[PMID: 28895394]
DU-145	IC₅₀	0.55 nM Compound: MMAE	Cytotoxicity against human DU-145 cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter-96 assay Cytotoxicity against human DU-145 cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter-96 assay	[PMID: 36327103]
DU-145	IC₅₀	0.62 nM Compound: MMAE	Cytotoxicity against human DU-145 cells assessed as reduction in cell viability incubated for 72 hrs in presence of TTR by CellTiter-96 assay Cytotoxicity against human DU-145 cells assessed as reduction in cell viability incubated for 72 hrs in presence of TTR by CellTiter-96 assay	[PMID: 36327103]
HeLa	IC₅₀	1 nM Compound: MMAE	Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs in presence of TTR by CellTiter-96 assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs in presence of TTR by CellTiter-96 assay	[PMID: 36327103]
HeLa	IC₅₀	1.1 nM Compound: MMAE	Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter-96 assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter-96 assay	[PMID: 36327103]
HGC-27	IC₅₀	7.18 nM Compound: MMAE	Cytotoxicity against KK-LC-1-negative human HGC-27 cells incubated for 72 hrs by CCK-8 assay Cytotoxicity against KK-LC-1-negative human HGC-27 cells incubated for 72 hrs by CCK-8 assay	[PMID: 35932567]
KB	IC₅₀	0.19 nM Compound: MMAE	Antiproliferative activity against human KB cells after 4 days by XTT assay Antiproliferative activity against human KB cells after 4 days by XTT assay	[PMID: 23845743]
KM-20L2	GI₅₀	0.599 nM Compound: 2b	Growth inhibition of human KM20L2 cells incubated for 48 hrs by MTT assay Growth inhibition of human KM20L2 cells incubated for 48 hrs by MTT assay	[PMID: 28211277]
KM-20L2	GI₅₀	0.599 nM Compound: Desmethylauristatin E	Growth inhibition of human KM20L2 cells after 48 hrs by SRB assay Growth inhibition of human KM20L2 cells after 48 hrs by SRB assay	[PMID: 28926240]
KM-20L2	GI₅₀	0.599 nM Compound: Desmethylauristatin E	Growth inhibition of human KM20L2 cells after 48 hrs by SRB assay Growth inhibition of human KM20L2 cells after 48 hrs by SRB assay	[PMID: 28895394]
L1210	IC₅₀	2.1 nM Compound: 2; MMAE	Cytotoxicity against mouse L1210 cells after 2 days by cell titer 96 aqueous one solution based assay Cytotoxicity against mouse L1210 cells after 2 days by cell titer 96 aqueous one solution based assay	[PMID: 29454703]
LNCaP	IC₅₀	0.71 nM Compound: MMAE	Cytotoxicity against human LNCaP cells assessed as reduction in cell viability incubated for 72 hrs in presence of TTR by CellTiter-96 assay Cytotoxicity against human LNCaP cells assessed as reduction in cell viability incubated for 72 hrs in presence of TTR by CellTiter-96 assay	[PMID: 36327103]
LNCaP	IC₅₀	0.79 nM Compound: MMAE	Cytotoxicity against human LNCaP cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter-96 assay Cytotoxicity against human LNCaP cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter-96 assay	[PMID: 36327103]
MCF7	GI₅₀	0.404 nM Compound: 2b	Growth inhibition of human MCF7 cells incubated for 48 hrs by MTT assay Growth inhibition of human MCF7 cells incubated for 48 hrs by MTT assay	[PMID: 28211277]
MCF7	GI₅₀	0.404 nM Compound: Desmethylauristatin E	Growth inhibition of human MCF7 cells after 48 hrs by SRB assay Growth inhibition of human MCF7 cells after 48 hrs by SRB assay	[PMID: 28926240]
MCF7	GI₅₀	0.404 nM Compound: Desmethylauristatin E	Growth inhibition of human MCF7 cells after 48 hrs by SRB assay Growth inhibition of human MCF7 cells after 48 hrs by SRB assay	[PMID: 28895394]
MDA-MB-231	IC₅₀	0.25 nM Compound: MMAE	Antiproliferative activity against human MDA-MB-231 cells after 4 days by XTT assay Antiproliferative activity against human MDA-MB-231 cells after 4 days by XTT assay	[PMID: 23845743]
MDA-MB-361	GI₅₀	0.49 nM Compound: 4, MMAE	Cytotoxicity against human MDA-MB-361 cells assessed as cell viability incubated fore 4 days by MTS assay Cytotoxicity against human MDA-MB-361 cells assessed as cell viability incubated fore 4 days by MTS assay	[PMID: 25431858]
MKN-45	IC₅₀	10.7 nM Compound: MMAE	Cytotoxicity against KK-LC-1-positive human MKN-45 cells incubated for 72 hrs by CCK-8 assay Cytotoxicity against KK-LC-1-positive human MKN-45 cells incubated for 72 hrs by CCK-8 assay	[PMID: 35932567]
NCI-H460	GI₅₀	0.683 nM Compound: 2b	Growth inhibition of human NCI-H460 cells incubated for 48 hrs by MTT assay Growth inhibition of human NCI-H460 cells incubated for 48 hrs by MTT assay	[PMID: 28211277]
NCI-H460	GI₅₀	0.683 nM Compound: Desmethylauristatin E	Growth inhibition of human NCI-H460 cells after 48 hrs by SRB assay Growth inhibition of human NCI-H460 cells after 48 hrs by SRB assay	[PMID: 28926240]
NCI-H460	GI₅₀	0.683 nM Compound: Desmethylauristatin E	Growth inhibition of human NCI-H460 cells after 48 hrs by SRB assay Growth inhibition of human NCI-H460 cells after 48 hrs by SRB assay	[PMID: 28895394]
NCI-H524	IC₅₀	3.7 nM Compound: MMAE	Cytotoxicity in human NCI-H524 cells pre-incubated for 2 hrs followed by compound wash out and subsequently incubated for 70 hrs by Cell Titer Glo assay Cytotoxicity in human NCI-H524 cells pre-incubated for 2 hrs followed by compound wash out and subsequently incubated for 70 hrs by Cell Titer Glo assay	[PMID: 30735385]
NCI-N87	GI₅₀	0.54 nM Compound: 4, MMAE	Cytotoxicity against human NCI-N87 cells assessed as cell viability incubated fore 4 days by MTS assay Cytotoxicity against human NCI-N87 cells assessed as cell viability incubated fore 4 days by MTS assay	[PMID: 25431858]
NUGC-4	IC₅₀	10.97 nM Compound: MMAE	Cytotoxicity against KK-LC-1-positive human NUGC-4 cells incubated for 72 hrs by CCK-8 assay Cytotoxicity against KK-LC-1-positive human NUGC-4 cells incubated for 72 hrs by CCK-8 assay	[PMID: 35932567]
PC-3	CC₅₀	0.97 nM Compound: MMAE	Cytotoxicity against human PC-3 cells not expressing PMSA measured using MTT assay Cytotoxicity against human PC-3 cells not expressing PMSA measured using MTT assay	[PMID: 34797052]
SF-268	GI₅₀	0.432 nM Compound: 2b	Growth inhibition of human SF268 cells incubated for 48 hrs by MTT assay Growth inhibition of human SF268 cells incubated for 48 hrs by MTT assay	[PMID: 28211277]
SF-268	GI₅₀	0.432 nM Compound: Desmethylauristatin E	Growth inhibition of human SF268 cells after 48 hrs by SRB assay Growth inhibition of human SF268 cells after 48 hrs by SRB assay	[PMID: 28926240]
SF-268	GI₅₀	0.432 nM Compound: Desmethylauristatin E	Growth inhibition of human SF268 cells after 48 hrs by SRB assay Growth inhibition of human SF268 cells after 48 hrs by SRB assay	[PMID: 28895394]
SK-OV-3	IC₅₀	0.66 nM Compound: 2; MMAE	Cytotoxicity against human SKOV3 cells after 2 days by cell titer 96 aqueous one solution based assay Cytotoxicity against human SKOV3 cells after 2 days by cell titer 96 aqueous one solution based assay	[PMID: 29454703]
U-87MG ATCC	EC₅₀	0.0002 μM Compound: Monomethyl auristatin E	Antiproliferative activity against human U87 cells after 72 hrs by MTS assay Antiproliferative activity against human U87 cells after 72 hrs by MTS assay	[PMID: 28972755]

体外研究
(In Vitro)

单甲基 auristatin E (MMAE) 在 CD30⁺ 在癌细胞内从 SGN-35 有效释放，并且由于其膜渗透性，能够对周围细胞发挥细胞毒活性^[1]。
MMAE 以与有丝分裂停滞相关的时间表和剂量依赖性的方式使结直肠癌细胞和胰腺癌细胞对 IR 敏感。放射增敏作用表现为受照射细胞中克隆形成存活率下降和 DNA 双链断裂增加^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

单甲基 auristatin E (MMAE) 与 IR 结合导致肿瘤生长延迟，肿瘤靶向 ACPP-cRGD-MMAE 与 IR 在异种移植模型中产生更稳健并显著延长的肿瘤消退^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

717.98

Formula

C₃₉H₆₇N₅O₇

CAS 号

474645-27-7

性状

固体

颜色

White to yellow

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

-20°C, sealed storage, away from moisture and light

*该产品在溶液状态不稳定，建议您现用现配，即刻使用。

溶解性数据

细胞实验：

Ethanol 中的溶解度 : 50 mg/mL (69.64 mM; 超声助溶)

DMSO 中的溶解度 : ≥ 48 mg/mL (66.85 mM; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

H₂O 中的溶解度 : < 0.1 mg/mL (insoluble)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.3928 mL	6.9640 mL	13.9280 mL
5 mM	0.2786 mL	1.3928 mL	2.7856 mL
10 mM	0.1393 mL	0.6964 mL	1.3928 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液；该产品在溶液状态不稳定，建议您现用现配，即刻使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 5% DMSO 40% PEG300 5% Tween-80 50% Saline
Solubility: 2.62 mg/mL (3.65 mM); 澄清溶液; 超声助溶
方案二

请依序添加每种溶剂： 5% DMSO 95% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.62 mg/mL (3.65 mM); 澄清溶液
方案三

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (3.48 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案四

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (3.48 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
方案五

请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (3.48 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。
方案六

请依序添加每种溶剂： 10% EtOH 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (3.48 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 EtOH 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案七

请依序添加每种溶剂： 10% EtOH 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (3.48 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 EtOH 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
方案八

请依序添加每种溶剂： 10% EtOH 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (3.48 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 EtOH 储备液加到 900 μL 玉米油中，混合均匀。
方案九

请依序添加每种溶剂： 1% DMSO 99% Saline
Solubility: ≥ 0.52 mg/mL (0.72 mM); 澄清溶液

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

*该产品在溶液状态不稳定，建议您现用现配，即刻使用。

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 99.97%

选择批次：

Data Sheet (649 KB) SDS (645 KB)

COA (295 KB) HNMR (206 KB) RP-HPLC (263 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Okeley, et al. Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate. Clinical Cancer Research (2010), 16(3), 888-897. [Content Brief]

[2]. Lisa Buckel, et al. Tumor radiosensitization by monomethyl auristatin E: mechanism of action and targeted delivery. Cancer Res. 2015 Apr 1;75(7):1376-87. [Content Brief]

Cell Assay ^[2]	Monomethyl auristatin E (MMAE, 5 nM) and ionizing radiation (IR) treated cells are harvested and lysed in RIPA buffer with protease and phosphatase inhibitors. Thirty μg of lysate undergo electrophoresis using 4-12% Bis-Tris gels, transferred to PVDF membranes and incubated with indicated primary antibodies. Blots are developed by ECL. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[2]	Mice^[2] 6-8 week old female athymic nu/nu mice are injected subcutaneously into thighs with 5×10⁶ HCT-116 or PANC-1 cells in a 1:1 Matrigel and PBS solution. Mice are treated with IR or intravenous (IV) injection of ACPP-cRGD-MMAE (6 nmoles/day, 18 nmoles total, i.v.), tumor tissue is harvested, formalin fixed and paraffin embedded followed by staining with indicated antibodies. The primary antibody is used at a 1:250 dilution and is visualized using DAB as a chromagen with the UltraMap system. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献	[1]. Okeley, et al. Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate. Clinical Cancer Research (2010), 16(3), 888-897. [Content Brief] [2]. Lisa Buckel, et al. Tumor radiosensitization by monomethyl auristatin E: mechanism of action and targeted delivery. Cancer Res. 2015 Apr 1;75(7):1376-87. [Content Brief]

Monomethyl auristatin E 相关分类

完整储备液配制表

* 请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液；该产品在溶液状态不稳定，建议您现用现配，即刻使用。

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO / Ethanol	1 mM	1.3928 mL	6.9640 mL	13.9280 mL	34.8199 mL
	5 mM	0.2786 mL	1.3928 mL	2.7856 mL	6.9640 mL
	10 mM	0.1393 mL	0.6964 mL	1.3928 mL	3.4820 mL
	15 mM	0.0929 mL	0.4643 mL	0.9285 mL	2.3213 mL
	20 mM	0.0696 mL	0.3482 mL	0.6964 mL	1.7410 mL
	25 mM	0.0557 mL	0.2786 mL	0.5571 mL	1.3928 mL
	30 mM	0.0464 mL	0.2321 mL	0.4643 mL	1.1607 mL
	40 mM	0.0348 mL	0.1741 mL	0.3482 mL	0.8705 mL
	50 mM	0.0279 mL	0.1393 mL	0.2786 mL	0.6964 mL
	60 mM	0.0232 mL	0.1161 mL	0.2321 mL	0.5803 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Monomethyl auristatin E474645-27-7MMAE SGD-1010 VedotinSGD1010SGD 1010SGD-1010Microtubule/TubulinADC CytotoxinApoptosisADC PayloadInhibitorinhibitorinhibit

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2024 MedChemExpress. All Rights Reserved.

Monomethyl auristatin E (Synonyms: MMAE; SGD-1010; Vedotin)

Customer Review

Other Forms of Monomethyl auristatin E:

MCE 顾客使用本产品发表的 40 篇科研文献

Monomethyl auristatin E 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 ADC Cytotoxin 亚型特异性产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Monomethyl auristatin E 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Monomethyl auristatin E (Synonyms: MMAE; SGD-1010; Vedotin)

Customer Review

Other Forms of Monomethyl auristatin E:

Monomethyl auristatin E 相关抗体

MCE 顾客使用本产品发表的 40 篇科研文献

Monomethyl auristatin E 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 ADC Cytotoxin 亚型特异性产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

Monomethyl auristatin E 相关抗体:

摩尔计算器

稀释计算器

Monomethyl auristatin E 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z